Literature DB >> 19388881

Pharmacological approaches to the treatment of obstructive sleep apnoea.

Malcolm Kohler1, Konrad E Bloch, John R Stradling.   

Abstract

BACKGROUND: Currently the treatment of choice for symptomatic obstructive sleep apnoea (OSA) is continuous positive airway pressure (CPAP). Some patients with OSA do not tolerate CPAP or have insufficiently severe symptoms to justify its use; for these patients, drug therapy would be a desirable potential therapeutic alternative.
OBJECTIVE: To summarize the current evidence on the effectiveness of drug therapy in patients with OSA.
METHODS: A systematic review of randomized controlled trials was performed to investigate the effects of drug therapy on OSA. RESULTS/
CONCLUSIONS: Searches of bibliographical databases revealed 33 trials investigating the effects of 27 different drugs on OSA severity and/or symptoms. The mechanisms by which these drugs are supposed to improve OSA include, amongst others, an increase in tone of the upper airways, an increase in ventilatory drive, a reduction in airway resistance, and alterations in surface tension forces in the upper airway. In most of these studies there was no significant effect on OSA observed. However, there is evidence from a few small trials that some drugs, especially those thought to increase upper airway muscle tone, have the potential to reduce OSA severity; but further data from larger studies of adequate duration are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19388881     DOI: 10.1517/13543780902877674

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  12 in total

1.  Drug trials for obstructive sleep apnea.

Authors:  Kingman P Strohl
Journal:  J Clin Sleep Med       Date:  2010-04-15       Impact factor: 4.062

Review 2.  Mechanisms of vascular damage in obstructive sleep apnea.

Authors:  Malcolm Kohler; John R Stradling
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

3.  CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea--therapeutic difficulties and dilemmas.

Authors:  Charalampos Mermigkis; Demetrios Mermigkis; Georgios Varouchakis; Sophia Schiza
Journal:  Sleep Breath       Date:  2011-01-09       Impact factor: 2.816

4.  Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.

Authors:  David W Carley; Bharati Prasad; Kathryn J Reid; Roneil Malkani; Hryar Attarian; Sabra M Abbott; Boris Vern; Hui Xie; Chengbo Yuan; Phyllis C Zee
Journal:  Sleep       Date:  2018-01-01       Impact factor: 5.849

Review 5.  Pharmacologic approaches for the management of symptoms and cardiovascular consequences of obstructive sleep apnea in adults.

Authors:  John M Dopp; Barbara J Morgan
Journal:  Sleep Breath       Date:  2010-06-28       Impact factor: 2.816

Review 6.  Obstructive Sleep Apnoea: From pathogenesis to treatment: Current controversies and future directions.

Authors:  Peter R Eastwood; Atul Malhotra; Lyle J Palmer; Eric J Kezirian; Richard L Horner; Mary S Ip; Robert Thurnheer; Nick A Antic; David R Hillman
Journal:  Respirology       Date:  2010-01-27       Impact factor: 6.424

7.  Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.

Authors:  Klaus J Wirth; Klaus Steinmeyer; Hartmut Ruetten
Journal:  Sleep       Date:  2013-05-01       Impact factor: 5.849

Review 8.  A resource of potential drug targets and strategic decision-making for obstructive sleep apnoea pharmacotherapy.

Authors:  Richard L Horner; Kevin P Grace; Andrew Wellman
Journal:  Respirology       Date:  2017-05-25       Impact factor: 6.424

9.  Chemogenetic stimulation of the hypoglossal neurons improves upper airway patency.

Authors:  Thomaz Fleury Curado; Kenneth Fishbein; Huy Pho; Michael Brennick; Olga Dergacheva; Luiz U Sennes; Luu V Pham; Ellen E Ladenheim; Richard Spencer; David Mendelowitz; Alan R Schwartz; Vsevolod Y Polotsky
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

10.  Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists.

Authors:  Ana P Abdala; John M Bissonnette; Adrian Newman-Tancredi
Journal:  Front Physiol       Date:  2014-05-30       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.